Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...226227228229230231232233234235236...10661067»
  • ||||||||||  hydrocortisone / Generic mfg.
    Enrollment open:  CRISP: Corticosteroids to Treat Pancreatitis (clinicaltrials.gov) -  Dec 1, 2022   
    P2,  N=86, Recruiting, 
    Trial completion date: Mar 2028 --> Sep 2029 | Trial primary completion date: Mar 2028 --> Sep 2029 Not yet recruiting --> Recruiting
  • ||||||||||  Emend intravenous (fosaprepitant) / Merck (MSD), Ono Pharma
    Trial completion, Trial completion date, Surgery:  Triple Therapy for Postoperative Nausea and Vomiting in Laparoscopic Gastrointestinal Surgery (clinicaltrials.gov) -  Dec 1, 2022   
    P3,  N=1154, Completed, 
    Recruiting --> Active, not recruiting | N=408 --> 174 Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Oct 2022
  • ||||||||||  dexamethasone / Generic mfg.
    Preclinical, Journal:  Tunable degrees of neurodegeneration in rats based on microsphere-induced models of chronic glaucoma. (Pubmed Central) -  Dec 1, 2022   
    Twenty-five rats received episcleral vein sclerosis injections (EPIm cohort) while the rest were injected in the eye anterior chamber with a suspension of biodegradable microspheres: 25 rats received non-loaded microspheres (N-L Ms cohort), 45 rats received microspheres loaded with dexamethasone (MsDexa cohort), and 43 rats received microspheres co-loaded with dexamethasone and fibronectin (MsDexaFibro cohort)...Using biodegradable microspheres models it is possible to generate tuned neurodegeneration. These results support the multifactorial nature of glaucoma based on several noxa.
  • ||||||||||  relacorilant (CORT125134) / Corcept Therap
    Journal:  Peripheral glucocorticoid receptor antagonism by relacorilant with modest HPA axis disinhibition. (Pubmed Central) -  Nov 30, 2022   
    In human HEK-293 cells, relacorilant potently antagonized dexamethasone- and cortisol-induced GR signaling, and in human peripheral blood mononuclear cells relacorilant largely prevented the anti-inflammatory effects of dexamethasone...This contrast between relacorilant and mifepristone is possibly due to the distinct transcriptional coregulator recruitment by the GR. In conclusion, relacorilant is thus an efficacious peripheral GR antagonist in mice with only modest disinhibition of the HPA axis, and the distinct properties of relacorilant endorse the potential of selective GR antagonist treatment for endogenous Cushing's syndrome.
  • ||||||||||  dexamethasone / Generic mfg.
    Trial completion date, Trial primary completion date, Surgery:  Intravenous and Perineural Dexamethasone for Brachial Plexus Block in Hand Surgery (clinicaltrials.gov) -  Nov 30, 2022   
    P1,  N=108, Recruiting, 
    In conclusion, relacorilant is thus an efficacious peripheral GR antagonist in mice with only modest disinhibition of the HPA axis, and the distinct properties of relacorilant endorse the potential of selective GR antagonist treatment for endogenous Cushing's syndrome. Trial completion date: Dec 2022 --> Jun 2023 | Trial primary completion date: Dec 2022 --> Jun 2023
  • ||||||||||  dexamethasone / Generic mfg., clonazepam / Generic mfg., levetiracetam / Generic mfg.
    Journal:  Myoclonus status revealing COVID 19 infection. (Pubmed Central) -  Nov 30, 2022   
    We believe that there is an inflammatory process involved with increased levels of proinflammatory cytokines and systemic inflammation, including cytokine storm or cytokine release syndrome targeting the brain and more specifically the cortex and basal ganglia [6]. Data collection in clinical registries is needed to increase our knowledge of the prevalence of neurological symptoms in patients with COVID-19 and will hopefully clarify the causal relationship between SARS-CoV-2 infection and post-COVID-19 myoclonic syndrome.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Disease-related compound identification based on deeping learning method. (Pubmed Central) -  Nov 30, 2022   
    The experimental results show that forgeNet performs better than support vector machines (SVM), random forest (RF), logical regression (LR), Naive Bayes (NB), XGBoost, LightGBM and gcForest. forgeNet could identify 19 compounds in Erhuang decoction (EhD) and Dexamethasone (DXMS) more accurately.
  • ||||||||||  Empliciti (elotuzumab) / AbbVie, BMS, Darzalex (daratumumab) / J&J, Ninlaro (ixazomib) / Takeda
    Outcomes of Second-Line (2L) Triplet+ Regimens in Patients with Relapsed/Refractory Multiple Myeloma (MM) Following Progression after First-Line (1L) Lenalidomide in the Connect® MM Disease Registry () -  Nov 29, 2022 - Abstract #ASH2022ASH_8073;    
    P=N/A
    RVd (31.5%), KRd (20.7%), and ixazomib (I)/Rd (18.0%) were the 3 most common R-containing regimens in 2L, and cyclophosphamide (C)/Vd (43.8%), DVd (12.4%), and KCd (7.9%) were the most common non-immunomodulatory drug regimens in 2L.Median follow-up since index ranged from 11.7 mo in the R-containing cohort to 13.1 mo in the P-containing cohort (Table 2)...This real-world analysis suggests that 2L P-containing regimens without class-switching to a non-immunomodulatory drug based regimen after progression on 1L R-containing regimens can lead to deep and durable responses. Further evaluations utilizing larger sample sizes, and/or more specific treatment subgroups are needed to confirm these findings.
  • ||||||||||  Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
    Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone () -  Nov 29, 2022 - Abstract #ASH2022ASH_8069;    
    Only 4 patients needed a supplement of 3 administrations of filgrastim. Pegfilgrastim was well tolerated in all patients: main side effects in our patients were mild fever and bone pain (21.2%).In patients affected by heavily pretreated MM treated with pomalidomide-dexamethasone, pegfilgrastim seems to reduce the incidence of severe neutropenia and infections and may increase the possibility to maintain the scheduled time of treatment.
  • ||||||||||  Kineret (anakinra) / SOBI, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Acute Clinical Syndrome of HLH in Patients with Hematologic Malignancy and EBV Infection () -  Nov 29, 2022 - Abstract #ASH2022ASH_8067;    
    Patients who survive initial HLH episode need to be closely monitored for recurrence. Preemptive strategies such as autologous stem cell transplant should be considered in eligible patients to further reduce the risk of relapse.
  • ||||||||||  diphenhydramine / Generic mfg., hydrocortisone / Generic mfg., paracetamol / Generic mfg.
    Granulocyte Transfusions in Children Undergoing Hematopoietic Stem Cell Transplantation () -  Nov 29, 2022 - Abstract #ASH2022ASH_7848;    
    We propose that in children undergoing HSCT, in the setting of prolonged neutropenia of any cause, GT can be helpful in ameliorating infectious complications like perianal cellulitis/fistulas, and bacterial or fungal blood stream infections. A larger prospective study is needed to address the effects of GT on overall survival.
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis
    Anti-CD 19 CAR-T Cell Therapy with Tisagenlecleucel for Ritcher Syndrome () -  Nov 29, 2022 - Abstract #ASH2022ASH_7826;    
    She received high dose chemotherapy with R-BEAM followed by autologous stem cell transplant, followed by 4 cycles of maintenance brentuximab given every 3 weeks for her CD30 positive large B cell lymphoma...Treatment was complicated by grade 1-2 cytokine release syndrome (CRS) (treated with tocilizumab and dexamethasone) requiring brief hospitalization...Venetoclax was added to ibrutinib and later, 2 cycles of Obinutuzumab were also given...She received 6 cycles of RCHOP in addition to venetoclax/ibrutinib but end of treatment PET showed disease progression...She received lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by CAR-T cell infusion with tis-cel 3.7 x 10^8 cells anti CD19 CAR-T cells on 6/7/21...She continues to be in CR now 1 year since her CAR-T cell infusion.Conclusion CAR-T cell therapy with Tisagenlecleucel shows promising activity in patients with RS. It is an evolving treatment strategy and more follow up is needed to assess the durability of the responses observed in these patients.
  • ||||||||||  Yescarta (axicabtagene ciloleucel) / Gilead, Daiichi Sankyo
    The Development of Carhlh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes () -  Nov 29, 2022 - Abstract #ASH2022ASH_7818;    
    Moreover, given the rarity of the syndrome, it is difficult to identify patients who are likely to develop carHLH prior to CAR T infusion. However, clinicians providing CAR T cell therapy should be aware of this emerging toxicity.
  • ||||||||||  Tasigna (nilotinib) / Novartis, Inhibikase
    Pro-Active 4SCAR2.0 Therapy with NGS-MRD Disease Monitoring in High-Risk B Cell Leukemia Management () -  Nov 29, 2022 - Abstract #ASH2022ASH_7802;    
    During the fourth round of chemotherapy (Methotrexate-Cytarabine-Dexamethasone), the patient suffered severe oral and intestinal mucositis, along with kidney and liver toxicity and required week-long dialysis... The combination of 4SCAR2.0 with NGS-MRD detection of tumor clones in the management of high-risk B-ALL appears to be safe and may be a logical option for patients not elected for HCT therapy.
  • ||||||||||  Darzalex (daratumumab) / J&J
    Data of Daratumumab from a Real-World Single-Center Study () -  Nov 29, 2022 - Abstract #ASH2022ASH_7748;    
    The major adverse events of daratumumab were myelosuppression, infusion-related adverse events, and infection. Conclusion The daratumuab-based regimens have good efficacy and safety in the treatment of plasma cell diseases.Key Words:plasma cell diseases; daratumuab; efficacy
  • ||||||||||  Sarclisa (isatuximab-irfc) / Sanofi
    Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study () -  Nov 29, 2022 - Abstract #ASH2022ASH_7737;    
    Background : Standard therapies for newly diagnosed multiple myeloma (NDMM) patients who are ineligible for autologous stem-cell transplantation (ASCT) have been lenalidomide-dexamethasone (Rd), bortezomib-lenalidomide-dexamethasone (VRd) or bortezomib-melphalan-prednisone (VMP)...Isatuximab is an anti-CD38 mAb approved in combination with pomalidomide-dexamethasone and carfilzomib-dexamethasone to treat relapsed/refractory MM, and has also shown clinical responses as combination therapy to treat NDMM (3).Corticosteroids have been the backbone of most myeloma targeted therapies since the discovery of their effectiveness in 1962...Isa-VRd shows encouraging preliminary efficacy in NDMM patients who are ineligible for transplant. Enrollment and follow-up is ongoing.
  • ||||||||||  Sarclisa (isatuximab-irfc) / Sanofi
    A Phase 2 Single-Arm Study to Evaluate the Efficacy of Isatuximab, Pomalidomide and Low-Dose Dexamethasone, in Patients with AL Amyloidosis Not in VGPR or Better after Any Previous Therapy (IsAMYP) () -  Nov 29, 2022 - Abstract #ASH2022ASH_7735;    
    P2
    Over the last 5 years, anti CD38 monoclonal antibodies (mAb), such as daratumumab (DARA), have emerged as breakthrough targeted therapies for pts with multiple myeloma (MM)...In AL amyloidosis, various groups demonstrated that pomalidomide (POM) is very effective and better tolerated than lenalidomide, especially in pts with renal insufficiency4,5 with no dose modification (4 mg)...Isatuximab (ISA) is another anti CD38 mAb that binds selectively to a unique epitope on the CD38 receptor and has been approved in RRMM in combination with POM or carfilzomib plus dexamethasone (DEX)6,7 with a good safety profile.Objective: The aim is to evaluate the efficacy and safety of the combination of ISA, POM, and low-dose DEX in pts with AL amyloidosis who did not reach at least very good partial response (VGPR) and/or relapsed.Material & Method s : In this multicenter, single-arm, phase 2 study, we planned to include 46 previously treated pts...DSMB meetings will be called every 6 months or whenever indicated.Conclusion : This is the first prospective study of ISA in combination with POM and low-dose DEX in AL amyloidosis. Accrual will be updated during the meeting, and patients' characteristics, preliminary results plus safety data will be reported